The U.S. Food and Drug Administration (FDA) warned consumers not to use off-brand versions of weight-loss drugs Ozempic, Rybelsus, and Wegovy because they may not have the same ingredients.
Those off-brand versions of the drugs are possibly unsafe or ineffective, the federal regulator said in a notice this week. Officials said they received reports of problems linked to “compounded” versions of semaglutide, the drug’s active ingredient.
